α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response
Tóm tắt
Circumstantial evidence points to a pathological role of alpha-synuclein (aSyn; gene symbol SNCA), conferred by aSyn misfolding and aggregation, in Parkinson disease (PD) and related synucleinopathies. Several findings in experimental models implicate perturbations in the tissue homeostatic mechanisms triggered by pathological aSyn accumulation, including impaired redox homeostasis, as significant contributors in the pathogenesis of PD. The nuclear factor erythroid 2-related factor (NRF2/Nrf2) is recognized as ‘the master regulator of cellular anti-oxidant response’, both under physiological as well as in pathological conditions. Using immunohistochemical analyses, we show a robust nuclear NRF2 accumulation in post-mortem PD midbrain, detected by NRF2 phosphorylation on the serine residue 40 (nuclear active p-NRF2, S40). Curated gene expression analyses of four independent publicly available microarray datasets revealed considerable alterations in NRF2-responsive genes in the disease affected regions in PD, including substantia nigra, dorsal motor nucleus of vagus, locus coeruleus and globus pallidus. To further examine the putative role of pathological aSyn accumulation on nuclear NRF2 response, we employed a transgenic mouse model of synucleionopathy (M83 line, expressing the mutant human A53T aSyn), which manifests widespread aSyn pathology (phosphorylated aSyn; S129) in the nervous system following intramuscular inoculation of exogenous fibrillar aSyn. We observed strong immunodetection of nuclear NRF2 in neuronal populations harboring p-aSyn (S129), and found an aberrant anti-oxidant and inflammatory gene response in the affected neuraxis. Taken together, our data support the notion that pathological aSyn accumulation impairs the redox homeostasis in nervous system, and boosting neuronal anti-oxidant response is potentially a promising approach to mitigate neurodegeneration in PD and related diseases.
Tài liệu tham khảo
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https://doi.org/10.1038/nrdp.2017.13
Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18:509. https://doi.org/10.1038/nrn.2017.91
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Goedert M, Jakes R, Spillantini MG (2017) The synucleinopathies: twenty years on. J Parkinsons Dis 7:S51–S69. https://doi.org/10.3233/JPD-179005
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. https://doi.org/10.1038/42166
Braak H, Rub U, Sandmann-Keil D, Gai WP, de Vos RA, Jansen Steur EN et al (2000) Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 99:489–495. https://doi.org/10.1007/s004010051150
Uchihara T, Giasson BI (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131:49–73. https://doi.org/10.1007/s00401-015-1485-1
Bose A, Beal MF (2016) Mitochondrial dysfunction in Parkinson’s disease. J Neurochem 139(Suppl 1):216–231. https://doi.org/10.1111/jnc.13731
Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38–48. https://doi.org/10.1038/nrn3406
Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson’s disease. Lancet Neurol 7:97–109. https://doi.org/10.1016/S1474-4422(07)70327-7
Wong YC, Krainc D (2017) alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23:1–13. https://doi.org/10.1038/nm.4269
Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394–406. https://doi.org/10.1038/nn.3350
Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 16:97–107. https://doi.org/10.1038/s41582-019-0301-2
Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4:600–609. https://doi.org/10.1038/ncpneuro0924
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD, (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269
Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:120–131. https://doi.org/10.1111/j.1749-6632.2003.tb07470.x
Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A et al (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389. https://doi.org/10.1111/j.1471-4159.1989.tb09133.x
Scudamore O, Ciossek T (2018) Increased oxidative stress exacerbates alpha-synuclein aggregation in vivo. J Neuropathol Exp Neurol 77:443–453. https://doi.org/10.1093/jnen/nly024
Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR et al (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61–69. https://doi.org/10.1196/annals.1427.036
Mitsuishi Y, Motohashi H, Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2:200. https://doi.org/10.3389/fonc.2012.00200
Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85:705–717. https://doi.org/10.1016/j.bcp.2012.11.016
Paladino S, Conte A, Caggiano R, Pierantoni GM, Faraonio R (2018) Nrf2 pathway in age-related neurological disorders: insights into MicroRNAs. Cell Physiol Biochem 47:1951–1976. https://doi.org/10.1159/000491465
Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP et al (2009) The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal 11:497–508. https://doi.org/10.1089/ARS.2008.2242
Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA et al (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66:75–85. https://doi.org/10.1097/nen.0b013e31802d6da9
Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM et al (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci U S A 101:3381–3386. https://doi.org/10.1073/pnas.0400282101
Todorovic M, Wood SA, Mellick GD (2016) Nrf2: a modulator of Parkinson’s disease? J Neural Transm (Vienna) 123:611–619. https://doi.org/10.1007/s00702-016-1563-0
Huang HC, Nguyen T, Pickett CB (2002) Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277:42769–42774. https://doi.org/10.1074/jbc.M206911200
Niture SK, Jain AK, Jaiswal AK (2009) Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci 122:4452–4464. https://doi.org/10.1242/jcs.058537
Niture SK, Khatri R, Jaiswal AK (2014) Regulation of Nrf2-an update. Free Radic Biol Med 66:36–44. https://doi.org/10.1016/j.freeradbiomed.2013.02.008
Corradini BR, Iamashita P, Tampellini E, Farfel JM, Grinberg LT, Moreira-Filho CA (2014) Complex network-driven view of genomic mechanisms underlying Parkinson’s disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra. Biomed Res Int 2014:543673. https://doi.org/10.1155/2014/543673
Durrenberger PF, Fernando FS, Kashefi SN, Bonnert TP, Seilhean D, Nait-Oumesmar B et al (2015) Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. J Neural Transm (Vienna) 122:1055–1068. https://doi.org/10.1007/s00702-014-1293-0
Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, de Andrade M et al (2007) A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 3:e98. https://doi.org/10.1371/journal.pgen.0030098
Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML et al (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2:52–73. https://doi.org/10.1126/scitranslmed.3001059
Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521–533. https://doi.org/10.1016/s0896-6273(02)00682-7
Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW et al (2014) Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A 111:10732–10737. https://doi.org/10.1073/pnas.1321785111
Jan A, Jansonius B, Delaidelli A, Bhanshali F, An YA, Ferreira N et al (2018) Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. Acta Neuropathol Commun 6:54. https://doi.org/10.1186/s40478-018-0554-9
Gene Expression Omnibus https://www.ncbi.nlm.nih.gov/geo/
Ferreira N, Goncalves NP, Jan A, Jensen NM, van der Laan A, Mohseni S et al (2021) Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain. Acta Neuropathol Commun 9:31. https://doi.org/10.1186/s40478-021-01131-8
Franklin KBJ, Paxinos G (2013) Paxinos and Franklin's The mouse brain in stereotaxic coordinates. Academic Press, an imprint of Elsevier, City
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
Jan A, Jansonius B, Delaidelli A, Somasekharan SP, Bhanshali F, Vandal M et al (2017) eEF2K inhibition blocks A beta 42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathol 133:101–119. https://doi.org/10.1007/s00401-016-1634-1
Calkins MJ, Vargas MR, Johnson DA, Johnson JA (2010) Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci 115:557–568. https://doi.org/10.1093/toxsci/kfq072
PhosphoSite https://www.phosphosite.org/proteinAction.action?id=3828&showAllSites=true
Numazawa S, Ishikawa M, Yoshida A, Tanaka S, Yoshida T (2003) Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am J Physiol Cell Physiol 285:C334-342. https://doi.org/10.1152/ajpcell.00043.2003
Fares MB, Jagannath S, Lashuel HA (2021) Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat Rev Neurosci 22:111–131. https://doi.org/10.1038/s41583-020-00416-6
McCann H, Stevens CH, Cartwright H, Halliday GM (2014) alpha-Synucleinopathy phenotypes. Parkinsonism Relat Disord 20(Suppl 1):S62-67. https://doi.org/10.1016/S1353-8020(13)70017-8
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752. https://doi.org/10.1074/jbc.M600933200
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164. https://doi.org/10.1038/ncb748
Muntane G, Ferrer I, Martinez-Vicente M (2012) alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 200:106–119. https://doi.org/10.1016/j.neuroscience.2011.10.042
Venderova K, Park DS (2012) Programmed cell death in Parkinson’s disease. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a009365
Lee OH, Jain AK, Papusha V, Jaiswal AK (2007) An auto-regulatory loop between stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol Chem 282:36412–36420. https://doi.org/10.1074/jbc.M706517200
Sorrentino ZA, Xia Y, Funk C, Riffe CJ, Rutherford NJ, Ceballos Diaz C et al (2018) Motor neuron loss and neuroinflammation in a model of alpha-synuclein-induced neurodegeneration. Neurobiol Dis 120:98–106. https://doi.org/10.1016/j.nbd.2018.09.005
Beraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA et al (2013) Microglial activation and antioxidant responses induced by the Parkinson’s disease protein alpha-synuclein. J Neuroimmune Pharmacol 8:94–117. https://doi.org/10.1007/s11481-012-9401-0
Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M et al (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401–410. https://doi.org/10.1016/s0002-9440(10)64553-1
Perni M, Galvagnion C, Maltsev A, Meisl G, Muller MB, Challa PK et al (2017) A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A 114:E1009–E1017. https://doi.org/10.1073/pnas.1610586114
Mateo I, Infante J, Sanchez-Juan P, Garcia-Gorostiaga I, Rodriguez-Rodriguez E, Vazquez-Higuera JL et al (2010) Serum heme oxygenase-1 levels are increased in Parkinson’s disease but not in Alzheimer’s disease. Acta Neurol Scand 121:136–138. https://doi.org/10.1111/j.1600-0404.2009.01261.x
Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rabano A, Kirik D et al (2012) alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson’s disease. Hum Mol Genet 21:3173–3192. https://doi.org/10.1093/hmg/dds143
Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-1 expression in idiopathic Parkinson’s disease. Exp Neurol 150:60–68. https://doi.org/10.1006/exnr.1997.6752
Lastres-Becker I, Garcia-Yague AJ, Scannevin RH, Casarejos MJ, Kugler S, Rabano A et al (2016) Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson’s disease. Antioxid Redox Signal 25:61–77. https://doi.org/10.1089/ars.2015.6549
Skibinski G, Hwang V, Ando DM, Daub A, Lee AK, Ravisankar A et al (2017) Nrf2 mitigates LRRK2- and alpha-synuclein-induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci U S A 114:1165–1170. https://doi.org/10.1073/pnas.1522872114
Tanji K, Maruyama A, Odagiri S, Mori F, Itoh K, Kakita A et al (2013) Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol 72:18–28. https://doi.org/10.1097/NEN.0b013e31827b5713
Yamazaki H, Tanji K, Wakabayashi K, Matsuura S, Itoh K (2015) Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol Int 65:210–219. https://doi.org/10.1111/pin.12261
Cook AL, Vitale AM, Ravishankar S, Matigian N, Sutherland GT, Shan J et al (2011) NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson’s disease. PLoS ONE 6:e21907. https://doi.org/10.1371/journal.pone.0021907
Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19:562–569
Moretti D, Tambone S, Cerretani M, Fezzardi P, Missineo A, Sherman LT et al (2021) NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington’s disease mouse model. Free Radic Biol Med 162:243–254. https://doi.org/10.1016/j.freeradbiomed.2020.10.022
Fu MH, Wu CW, Lee YC, Hung CY, Chen IC, Wu KLH (2018) Nrf2 activation attenuates the early suppression of mitochondrial respiration due to the alpha-synuclein overexpression. Biomed J 41:169–183. https://doi.org/10.1016/j.bj.2018.02.005
Hoenen C, Gustin A, Birck C, Kirchmeyer M, Beaume N, Felten P et al (2016) Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS ONE 11:e0162717. https://doi.org/10.1371/journal.pone.0162717
O’Connell MA, Hayes JD (2015) The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 43:687–689. https://doi.org/10.1042/BST20150069
Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A et al (2016) Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson’s-like disease. J Neurosci 36:6332–6351. https://doi.org/10.1523/JNEUROSCI.0426-16.2016
Barone MC, Sykiotis GP, Bohmann D (2011) Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson’s disease. Dis Model Mech 4:701–707. https://doi.org/10.1242/dmm.007575
Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85:919–934. https://doi.org/10.1002/jnr.21191
Delaidelli A, Jan A, Herms J, Sorensen PH (2019) Translational control in brain pathologies: biological significance and therapeutic opportunities. Acta Neuropathol 137:535–555. https://doi.org/10.1007/s00401-019-01971-8
Heise C, Taha E, Murru L, Ponzoni L, Cattaneo A, Guarnieri FC et al (2016) eEF2K/eEF2 pathway controls the excitation/inhibition balance and susceptibility to epileptic seizures. Cereb Cortex: https://doi.org/10.1093/cercor/bhw075
Liu R, Proud CG (2016) Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. Acta Pharmacol Sin 37:285–294. https://doi.org/10.1038/aps.2015.123